drugset / Trial / NCT04354727
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is a designed to evaluate safety and activity of APG-1252 when administered as monotherapy and in combination with ruxolitinib in previously ruxolitinib treated myelofibrosis patients.
Timeline
- Start
- 2020-12-15
- Primary completion
- 2022-12-15
- Completion
- 2023-06-15
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pelcitoclax | Small molecule | 80 mg | Intravenous |
| Subject | Pelcitoclax | Small molecule | 160 mg | Intravenous |
| Subject | Pelcitoclax | Small molecule | 240 mg | Intravenous |
| Background | Ruxolitinib | Small molecule | — | Oral |